gsk-2816126 and Colonic-Neoplasms

gsk-2816126 has been researched along with Colonic-Neoplasms* in 2 studies

Other Studies

2 other study(ies) available for gsk-2816126 and Colonic-Neoplasms

ArticleYear
Targeting EZH2 histone methyltransferase activity alleviates experimental intestinal inflammation.
    Nature communications, 2019, 06-03, Volume: 10, Issue:1

    Enhancer of zeste homolog 2 (EZH2)-mediated trimethylation of histone 3 lysine 27 (H3K27Me3) is critical for immune regulation. However, evidence is lacking to address the effect of EZH2 enzyme's activity on intestinal immune responses during inflammatory bowel disease (IBD). Here we report that suppressing EZH2 activity ameliorates experimental intestinal inflammation and delayed the onset of colitis-associated cancer. In addition, we identified an increased number of functional MDSCs in the colons, which are essential for EZH2 inhibitor activity. Moreover, inhibition of EZH2 activity promotes the generation of MDSCs from hematopoietic progenitor cells in vitro, demonstrating a previously unappreciated role for EZH2 in the development of MDSCs. Together, these findings suggest the feasibility of EZH2 inhibitor clinical trials for the control of IBD. In addition, this study identifies MDSC-promoting effects of EZH2 inhibitors that may be undesirable in other therapeutic contexts and should be addressed in a clinical trial setting.

    Topics: Animals; Cell Differentiation; Colitis; Colon; Colonic Neoplasms; Dextran Sulfate; Enhancer of Zeste Homolog 2 Protein; Enzyme Inhibitors; Female; Hematopoietic Stem Cells; Histone Code; Histones; In Vitro Techniques; Indazoles; Indoles; Inflammatory Bowel Diseases; Methylation; Mice; Myeloid-Derived Suppressor Cells; Pyridones

2019
Large variety in a panel of human colon cancer organoids in response to EZH2 inhibition.
    Oncotarget, 2016, Oct-25, Volume: 7, Issue:43

    EZH2 inhibitors have gained great interest for their use as anti-cancer therapeutics. However, most research has focused on EZH2 mutant cancers and recently adverse effects of EZH2 inactivation have come to light. To determine whether colorectal cancer cells respond to EZH2 inhibition and to explore which factors influence the degree of response, we treated a panel of 20 organoid lines derived from human colon tumors with different concentrations of the EZH2 inhibitor GSK126. The resulting responses were associated with mutation status, gene expression and responses to other drugs. We found that the response to GSK126 treatment greatly varied between organoid lines. Response associated with the mutation status of ATRX and PAX2, and correlated with BIK expression. It also correlated well with response to Nutlin-3a which inhibits MDM2-p53 interaction thereby activating p53 signaling. Sensitivity to EZH2 ablation depended on the presence of wild type p53, as tumor organoids became resistant when p53 was mutated or knocked down. Our exploratory study provides insight into which genetic factors predict sensitivity to EZH2 inhibition. In addition, we show that the response to EZH2 inhibition requires wild type p53. We conclude that a subset of colorectal cancer patients may benefit from EZH2-targeting therapies.

    Topics: Animals; Apoptosis Regulatory Proteins; Cell Line, Tumor; Colonic Neoplasms; Enhancer of Zeste Homolog 2 Protein; Humans; Indoles; Membrane Proteins; Mice; Mitochondrial Proteins; Mutation; Organoids; PAX2 Transcription Factor; Pyridones; Tumor Suppressor Protein p53; X-linked Nuclear Protein

2016